Screener
CRISPR Therapeutics CRSP Operating Lease ROU Assets
Operating Lease ROU Assets at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | As of / March 31, 2026 | As of / December 31, 2025 |
|---|---|---|
| Total current assets | 2,448,362 | 1,985,671 |
| Property and equipment, net | 112,175 | 115,851 |
| Restricted cash | 7,629 | 7,629 |
| Operating lease assets | 128,671 | 131,724 |
| Other non-current assets | 28,983 | 24,368 |
| Total assets | $2,725,820 | $2,265,243 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's operating lease ROU assets?
- CRISPR Therapeutics (CRSP) reported operating lease ROU assets of $128.67M in Q1 2026.
- How has CRISPR Therapeutics's operating lease ROU assets changed year-over-year?
- CRISPR Therapeutics's operating lease ROU assets decreased by 8.3% year-over-year, from $140.28M to $128.67M.
- What is the long-term trend for CRISPR Therapeutics's operating lease ROU assets?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's operating lease ROU assets has grown at a 21.0% compound annual growth rate (CAGR), from $50.87M to $131.72M.
- What does operating lease ROU assets mean?
- Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.
Ask your AI about CRISPR Therapeutics's operating lease rou assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude